Overall, mutated SF3B1 has been detected in hematological malignancies and solid tumors and has been proven to be related to patient prognosis, abnormal transcription, alternative splicing, and sensitivity to SF3B small-molecule inhibitors. The gene discussed is SF3B1; the disease is hematologic disorder.